685091-51-4 Usage
Imidazole ring
The compound contains a 5-membered imidazole ring, which is an aromatic heterocyclic ring with 2 nitrogen atoms.
Carboxylic acid group
The compound has a carboxylic acid group (-COOH) attached to the imidazole ring, which is known for its acidic properties.
Bromophenylmethyl group
The compound has a bromine atom attached to a phenyl ring, which is connected to the imidazole ring through a methylene group (-CH2-).
Hydroxyisopropyl group
The compound has a hydroxyl group (-OH) attached to a isopropyl group (1-methylethyl), which is connected to the imidazole ring.
Propyl group
The compound has a propyl group (3-carbon alkyl chain) attached to the hydroxyisopropyl group.
Ethyl ester
The compound is an ethyl ester, meaning it has an ethoxy group (-OCH2CH3) attached to the carboxylic acid group.
Pharmaceutical use
Due to its unique structure and potential biological activity, the compound may be used as a pharmaceutical ingredient or in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 685091-51-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,5,0,9 and 1 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 685091-51:
(8*6)+(7*8)+(6*5)+(5*0)+(4*9)+(3*1)+(2*5)+(1*1)=184
184 % 10 = 4
So 685091-51-4 is a valid CAS Registry Number.
685091-51-4Relevant articles and documents
Convergent Synthesis of Angiotensin II Receptor Blockers through C-H Arylation of 1-Benzyl-5-phenyl-1 H -tetrazole with Functionalized Aryl Bromides
Seki, Masahiko,Takahashi, Yusuke
, p. 2689 - 2692 (2021)
Highly convergent synthesis of angiotensin II receptor blockers has been accomplished by means of late-stage C-H arylation using functionalized aryl bromides. C-H arylation of 1-benzyl-5-phenyl-1 H -tetrazole with aryl bromides carrying methyl 2-ethoxyben
A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE COMPOUNDS
-
Page/Page column 4, (2008/06/13)
A process for the preparation of olmesartan medoxomil, and derivatives thereof, by use of novel phenyltetrazole intermediates.
